Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BIAF | 8-K | bullish | 5/10 | bioAffinity Technologies reported that sales of its CyPath Lung test more than doubled year-over-year through Q3 2026, w | Oct 6, 2026 |
| MAIA | 8-K | neutral | 2/10 | MAIA Biotechnology filed an 8-K furnishing a corporate presentation and summary under Regulation FD, posted to its websi | Oct 6, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its ongoing buyback program. The | Oct 6, 2026 |
| SXTP | PRESS-RELEASE | neutral | 6/10 | 60 Degrees Pharmaceuticals announced it will conclude enrollment in its Phase 2 severe babesiosis study at 30 patients ( | Oct 6, 2026 |
| AVBP | 8-K | bearish | 7/10 | ArriVent announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did | Oct 6, 2026 |
| PDSB | 8-K | neutral | 3/10 | PDS Biotechnology filed an 8-K announcing a virtual KOL event on October 15, 2026, to discuss Phase 2 clinical outcomes | Oct 6, 2026 |
| TELO | 8-K | neutral | 5/10 | Telomir Pharmaceuticals closed a ~$5.6M PIPE financing on October 5, 2026, issuing 4,843,300 common shares at $1.16/shar | Oct 6, 2026 |
| ENTX | 8-K | neutral | 3/10 | Entera Bio appointed former Gilead and Amgen executive Laura Hamill to its Board of Directors, effective December 1, 202 | Oct 6, 2026 |
| GALT | PRESS-RELEASE | bullish | 7/10 | Galectin Therapeutics announced it submitted a registrational Phase 3 protocol for belapectin (MASH cirrhosis/portal hyp | Oct 6, 2026 |
| REGN | 8-K | bullish | 7/10 | Regeneron and Sanofi expanded their antibody collaboration via the Sixth Amendment, with Sanofi paying a $1.0B upfront a | Oct 6, 2026 |
| SXTP | 8-K | neutral | 5/10 | 60 Degrees Pharmaceuticals announced it will conclude enrollment in its randomized severe babesiosis study at 30 patient | Oct 6, 2026 |
| KAPA | 8-K | bullish | 6/10 | Kairos Pharma reported positive interim Phase 2 data for ENV-105 (carotuximab) in metastatic castration-resistant prosta | Oct 6, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio announced FDA acceptance of its NDA for oral infigratinib in achondroplasia with Priority Review and a PDUFA d | Oct 6, 2026 |
| SCYX | PRESS-RELEASE | neutral | 4/10 | SCYNEXIS announced completion of a Phase 1 study for SCY-770, a first-in-class oral direct AMPK activator for ADPKD, sho | Oct 6, 2026 |
| SLGL | 6-K | neutral | 3/10 | Sol-Gel Technologies filed its proxy statement for the Annual Meeting of Shareholders scheduled for November 17, 2026. T | Oct 6, 2026 |
| INDV | 425 | neutral | 4/10 | Indivior filed a supplemental 8-K/425 to update the joint proxy statement/prospectus for its pending merger with Supernu | Oct 6, 2026 |
| SUPN | 425 | neutral | 4/10 | Supernus filed a supplemental proxy statement to address stockholder litigation alleging disclosure deficiencies in the | Oct 6, 2026 |
| INDV | 8-K | neutral | 3/10 | Indivior filed an 8-K supplementing its joint proxy statement/prospectus for the pending merger with Supernus, adding su | Oct 6, 2026 |
| SUPN | DEFA14A | neutral | 3/10 | Supernus filed a DEFA14A supplementing its merger proxy statement with Indivior to address stockholder litigation allegi | Oct 6, 2026 |
| PMN | PRESS-RELEASE | neutral | 3/10 | ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino b | Oct 6, 2026 |
| KMDA | 6-K | neutral | 4/10 | Kamada announced the commercial launch of two new biosimilar products in Israel: Ustekinumab-Kamada (biosimilar to Stela | Oct 6, 2026 |
| OKYO | 6-K | bullish | 6/10 | OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE pivotal trial of urcosimod for neuropathic corneal | Oct 6, 2026 |
| BHC | PRESS-RELEASE | neutral | 1/10 | Bausch Health Companies Inc. announced it will report its Q3 2026 results on October 28, 2026. | Oct 6, 2026 |
| KMDA | PRESS-RELEASE | bullish | 6/10 | Kamada announced the commercial launch of two new biosimilars in Israel (Ustekinumab-Kamada and Enoxaparin-Kamada), expa | Oct 6, 2026 |
| OKYO | PRESS-RELEASE | bullish | 6/10 | OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NC | Oct 6, 2026 |
| QNTM | 6-K | neutral | 4/10 | Quantum BioPharma announced it has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research b | Oct 6, 2026 |
| QNTM | PRESS-RELEASE | neutral | 4/10 | Quantum BioPharma announced a Study Start-Up Agreement with Thermo Fisher's PPD clinical research business to initiate i | Oct 6, 2026 |
| LBRX | EFFECT | bearish | 5/10 | The SEC declared effective LB Pharmaceuticals' registration statement on Form S-3 (File No. 333-294900) on October 5, 20 | Oct 6, 2026 |
| SCNI | EFFECT | bearish | 5/10 | The SEC declared effective Scinai Immunotherapeutics Ltd.'s F-1 registration statement (File No. 333-299112) on October | Oct 6, 2026 |
| GMAB | SC 13G | neutral | 4/10 | Darwin Global Management, Ltd. and related entities filed a new Schedule 13G disclosing a 5.9% passive stake in Genmab A | Oct 5, 2026 |